View On Demand

A New Drug Platform That Helps Cancer Immunotherapies Work Better

About the Event

Targeted Immunotherapy has the promise to transform cancer treatment. Currently, however, only a minority of patients achieve long-lasting benefit from immunotherapy because tumor antigens adapt and hide from therapies over time.

BryoLogyx is developing bryostatin, a platform of tumor and antigen stimulating drugs that improve the efficacy of cancer immunotherapies. Bryostatin makes the tumors more “visible” to therapeutics by increasing the expression of cell surface antigens. This makes tumors easier to target and kill. Bryostatin has been the subject of numerous clinical trials in more than 1,100 patients and has an established safety profile.

Join our webinar with Bryologyx Founder and CEO, Thomas Loarie to hear more about the science behind bryostatin and why the company attained the exclusive license for use in cancer, inflammatory, autoimmune, and infectious diseases.

View On-Demand


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.